EYEGENE Inc.

Technology Commercialization

2011~Present

'22.02
Licensing agreement with BMI Korea for EG-HZ
'22.02
SAHPRA(South Africa) IND filing for EG-COVID
phase 1/2a clinical trials
'22.01
HREC(Australia) approval for EG-COVID
phase 1/2a clinical trials
'21.08
MFDS Approval for EG-COVID (COVID-19)
phase 1/2a clinical trials
'21.07
Completed phase 2 clinical trial for EG-Mirotin
in Korea
'21.06
Completed phase 1 clinical trial for EG-HZ
in Australia
'20.05
Started development of mRNA-based COVID-19 vaccine (EG-COVID)
'20.03
MFDS Approval for EG-Mirotin (Diabetic Retinopathy) phase 2 clinical trials
'19.12
HREC(Australia) approval for EG-HZ (Herpes Zoster) phase 1 clinical trials
'19.02
MFDS Approval for EG-Myocin (Myocardial Ischemia/ Reperfusion Injury) phase 2 clinical trials
'18.10
MFDS Approval for EG-Decorin (Wound Healing) phase 2 clinical trials
'17.11
MFDS Approval for EG-Myocin (Myocardial Ischemia/ Reperfusion Injury) phase 1 clinical trials & Completion (’18.04)
'16.11
Relocated and Expanded R&D Center
'15.11
Listing on KOSDAQ Exchange
'14.06
EMA Approval for EG-Mirotin (Diabetic Retinopathy) phase 2a clinical trials
'13.11
Public Listing on KONEX Exchange
'13.10
Licensing agreement with GeneMatrix for Diabetic Retinopathy Diagnostic Kit
'13.01
MFDS Approval for EG-Decorin (Pressure Ulcer) phase 1/2 clinical trials
'12.12
EMA Approval for EG-Mirotin (Diabetic Retinopathy) phase 1 clinical trials & Completion (‘14.05)
'12.09
MFDS Approval for EG-HPV (Cervical Cancer Vaccine) phase 1 clinical trials & Completion (‘14.05)

Strengthening Technological Competitiveness

2007~2010

Development of R&D infrastruc

Established~2006

About us